The Goldman Sachs Group Issues Positive Forecast for Elevance Health (NYSE:ELV) Stock Price

Key Points

• The Goldman Sachs Group raised its price target on Elevance Health to $370 (from $350) while maintaining a "neutral" rating, implying roughly a 7% upside from the prior close.
• Elevance beat Q1 estimates with EPS of $12.58 (vs. $10.74 expected) and stronger-than-expected revenue, and it raised its FY‑2026 adjusted EPS outlook, citing medical-cost controls, AI-driven operating improvements and higher investment income as drivers.
• Analyst sentiment is mixed—MarketBeat shows a consensus "Hold" with an average target of $384.65—and a law firm has opened an investor investigation, adding potential regulatory/legal overhang.

Elevance Health (NYSE:ELV - Get Free Report) had its target price boosted by investment analysts at The Goldman Sachs Group from $350.00 to $370.00 in a note issued to investors on Friday,MarketScreener reports. The firm presently has a "neutral" rating on the stock. The Goldman Sachs Group's price objective would indicate a potential upside of 7.05% from the company's previous close.

ELV has been the topic of a number of other research reports. Leerink Partners set a $364.00 target price on Elevance Health in a report on Thursday. Mizuho lowered their target price on Elevance Health from $413.00 to $350.00 and set an "outperform" rating on the stock in a report on Wednesday, March 11th. Guggenheim reaffirmed a "buy" rating and issued a $399.00 target price on shares of Elevance Health in a report on Friday. JPMorgan Chase & Co. raised their target price on Elevance Health from $394.00 to $397.00 and gave the company an "overweight" rating in a report on Monday, February 2nd. Finally, Jefferies Financial Group decreased their price objective on Elevance Health from $395.00 to $391.00 and set a "buy" rating on the stock in a report on Monday. Eleven research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $384.65.

Elevance Health Stock Performance

ELV traded down $0.67 during midday trading on Friday, reaching $345.62. The company's stock had a trading volume of 159,449 shares, compared to its average volume of 1,858,392. The stock has a market cap of $75.92 billion, a P/E ratio of 14.67, a PEG ratio of 1.83 and a beta of 0.49. The company has a fifty day simple moving average of $309.00 and a 200 day simple moving average of $331.66. The company has a current ratio of 1.48, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health has a twelve month low of $273.71 and a twelve month high of $427.54.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company's revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts expect that Elevance Health will post 25.5 earnings per share for the current year.

Institutional Trading of Elevance Health

Institutional investors have recently bought and sold shares of the stock. Physician Wealth Advisors Inc. boosted its stake in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock valued at $26,000 after buying an additional 63 shares in the last quarter. Rossby Financial LCC boosted its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock valued at $28,000 after buying an additional 44 shares in the last quarter. Activest Wealth Management boosted its stake in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock valued at $27,000 after buying an additional 34 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Elevance Health in the 4th quarter valued at $31,000. Finally, J.Safra Asset Management Corp acquired a new stake in Elevance Health in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 89.24% of the company's stock.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results and guidance lift sentiment — ELV reported better-than-expected Q1 EPS and raised its 2026 adjusted EPS outlook (targets 12% EPS growth in 2027), signaling stronger profitability and upward earnings momentum. Elevance raises 2026 adjusted EPS outlook
• Positive Sentiment: Management cites medical-cost controls and AI-driven operating discipline as drivers of margin expansion and a higher annual profit forecast — supports sustainable margin improvement. Health insurer Elevance raises annual profit forecast
• Positive Sentiment: Investment income helped EPS — rising net investment income materially boosted Q1 results, offsetting some membership pressure. ELV Beats Q1 on rising net investment income
• Positive Sentiment: Analyst support: Evercore raised its price target to $360, adding buy-side validation for the beat-and-raise story. Evercore raises price target on Elevance
• Positive Sentiment: Shareholder return: Board declared a quarterly dividend (supports income-oriented investors and reduces downside risk).
• Neutral Sentiment: Analyst stance mixed — Robert W. Baird raised its target to $331 but moved to a "neutral" rating, reflecting more cautious near-term expectations despite higher valuation work. Baird updates target and rating
• Neutral Sentiment: Operational caveat: Management noted membership declines; the topline impact is being offset by investment income and cost controls — watch membership trends for sustainability. Valuation and mixed Q1 draw attention
• Negative Sentiment: Legal risk: A law firm (Kirby McInerney LLP) has launched an investor investigation into potential securities-law claims involving Elevance and senior management — introduces regulatory/legal overhang and potential litigation risk. Investor alert: Kirby McInerney investigates Elevance

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.